COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY

1 . A method for the therapeutic or prophylactic treatment of (a) when X is N, Duchenne muscular dystrophy, Becker muscular dystrophy, or cachexia, or (b) when X is CR x , Duchenne muscular dystrophy or Becker muscular dystrophy, comprising administering a compound of formula (I):

or a tautomer, enantiomer, pharmaceutically acceptable salt, hydrate, solvate, complex, or prodrug thereof, wherein

X is CR x or N;

R x is H or C 1 -C 6 alkyl;

L 1 is a bond, —(CR 5 R 5 ) n —, —NR 5 —, —O—, —S—, —(CR 5 R 5 ) n NR 5 —, —C(O)NR 5 —, —C(O)NR 5 O—, —C(S)NR 5 —, —NR 5 C(O)—, —NR 5 C(S)—, —NR 5 C(NH)—, —SO 2 NR 5 —, —NR 5 SO 2 —, —C(O)—, —C(S)—, —SO—, —SO 2 —, —CR 5 ═CR 5 —, —C≡C—, —NR 5 C(O)NR 5 —, —NR 5 C(S)NR 5 —, —NR 5 C(NH)NR 5 —, —NR 5 C(O)O—, or —OC(O)NR 5 —;

R 1 is C 1 -C 10 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl, each of which is optionally substituted with one or more OR S , N(R 5 ) 2 , R 6 , or OR 6 ; or

R 1 is an optionally substituted 5-10 membered mono- or bicyclic aromatic or 4-7 membered non-aromatic carbocyclic or heterocyclic ring system;

L 2 is —(CR 5 R 5 ) n —, —(CR 5 R 5 ) n O—, —C(O)—, —C(NR 5 )—, —SO 2 —, —C(O)NR 5 —, or —SO 2 NR 5 —;

R 2 is C 1 -C 10 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl, each of which is optionally substituted with optionally substituted 5-10 membered mono- or bicyclic aromatic or 4-7 membered non-aromatic carbocyclic or heterocyclic ring system; or

R 2 is an optionally substituted 5-10 membered mono- or bicyclic aromatic or 4-7 membered non-aromatic carbocyclic or heterocyclic ring system;

Each of R 3 and R 4 is independently hydrogen, C 1 -C 6 alkyl, OH, —O(C 1 -C 6 alkyl), halo, SO m R 5 , or NR 5 R 5 ; or

R 3 and R 4 together with the carbon atoms to which they are attached form a 5-6 membered aromatic or 5-7 membered non-aromatic carbocyclic or heterocyclic ring system, each of which is optionally substituted with one or more C 1 -C 6 alkyl, OH, —O(C 1 -C 6 alkyl), halo, SO m R 5 , C(O)R 5 , or NR 5 R 5 ;

m is 0, 1, or 2;

n is 1 or 2;

each R 5 is independently H or C 1 -C 6 alkyl optionally substituted with one or more halo; and

R 6 is an optionally substituted 5-10 membered mono- or bicyclic aromatic or 4-7 membered non-aromatic carbocyclic or heterocyclic ring system.

2 . The method of claim 1 , wherein L 1 is a bond, —CH 2 —, —CH 2 CH 2 —, —C(O)NR 5 —, —C(S)NR 5 —, —NR 5 —C(O)—NR 5 —, —NR 5 C(O)—, —C(O)—, —NR 5 —SO 2 —, —C(O)NR 5 —O—, —S—, —SO 2 —, or —CH 2 NR 5 —; where R 5 is H or C 1 -C 4 alkyl.

3 - 4 . (canceled)

5 . The method of claim 1 , wherein R 1 is a 5-10 membered mono- or bicyclic aromatic or 4-7 membered non-aromatic carbocyclic or heterocyclic ring system, each of which is unsubstituted or substituted with one or more R 5 , R 6 , —C(O)NR 5 R 5 , C(O)NHR 6 , —NR 5 C(O)R 5 , —NR 5 C(O)R 6 , —C(O)OR 5 , —C(O)OR 6 , —C(O)R 5 , —C(O)R 6 , —(CH 2 ) q OR 5 , —(CH 2 ) q OR 6 , —SO 2 R 5 , —SO 2 R 6 , halo, or CN, wherein q is 0, 1, or 2.

6 . The method of claim 5 , wherein R 1 is (i) phenyl, pyridine, pyrimidine, pyridazine, pyrrole, furan, thiophene, benzofuran, benzothiazole, benzodioxolane, benzodioxyl, benzodioxane, thiadiazole, isoxazole, cyclopropyl, cyclobutyl, piperazine, pyrrolidine, pyrrolidinone, piperidine, piperazine, morpholine, thiazole, naphthalene, quinoxaline, quinoline, benzoxazole, indane, or tetrahydronaphthalene, each of which is optionally substituted with one or more CONH 2 , CON(CH 3 ) 2 , CONH(C 1 -C 3 alkyl), CO(C 1 -C 3 alkyl), C(O)heterocyclyl, COOH, COO(C 1 -C 3 alkyl), SO 2 CH 3 , CH 2 CH 2 OH, O(C 1 -C 3 alkyl), —NHC(O)(C 1 -C 3 alkyl), heterocyclyl, phenoxy, C 1 -C 3 alkyl, (CH 2 ) q OH, (CH 2 ) q O-phenyl, cyano, or halo; or

(ii) R 1 is

7 - 8 . (canceled)

9 . The method of claim 1 , wherein R 1 is —(CH 2 )—R 6 or —(CH 2 ) 2 —R 6 , wherein R 6 is phenyl, furan, or tetrahydrofuran, each of which is optionally substituted with one or more C 1 -C 3 alkyl, O(C 1 -C 3 alkyl), or halo.

10 . The method of claim 1 , wherein L 2 is —(CH 2 ) r —, —(CH 2 ) r O—, —C(O)— or SO 2 —, wherein r is 1, 2 or 3.

11 - 12 . (canceled)

13 . The method of claim 1 , wherein R 2 is an optionally substituted 5- or 6-membered aromatic or non-aromatic cyclic group.

14 . The use method of claim 13 , wherein R 2 is phenyl, pyridine, piperidine, cyclohexyl, pyrimidine, thiophene, isoxazole, or oxadiazole, each of which is optionally substituted with one or more halo, cyano, R 7 , C(O)NR 5 R 7 , —C(O)R 7 , —SO 2 NR 5 R 7 , —SO 2 N(R 5 )(OR 7 ), —(CR 5 R 5 ) q R 7 , —SO 2 R 7 , —(CR 5 R 5 ) q OR 7 or —O(CR 5 R 5 ) 9 R 7 ; wherein

R 5 is H or C 1 -C 4 alkyl;

R 7 is (i) H or C 1 -C 6 alkyl, cycloalkyl, heterocyclyl, aryl, aralkyl, or heteroaryl, wherein the alkyl, cycloalkyl, heterocyclyl, aryl, aralkyl, and heteroaryl are each optionally substituted with one or more halo or —O(C 1 -C 6 alkyl); and wherein the cycloalkyl, heterocyclyl, aryl, aralkyl, and heteroaryl are each optionally substituted with one or more C 1 -C 6 alkyl; or (ii) C 1 -C 4 alkyl, C 1 -C 4 alkenyl, or C 1 -C 4 alkynyl; or (iii) methyl, trifluoromethyl, ethyl, propyl, isopropyl, t-butyl, 2-propenyl, or 2-propynyl; or (iv) phenyl, benzodioxolane, pyrrolidine, morpholine, piperidine, or pyrrolidinedione; or

when R 5 and R 7 are attached to the same nitrogen atom, R 5 and R 7 may be combined with that nitrogen atom to form a 4 to 7 membered saturated or unsaturated ring system which may contain one or more additional heteroatoms.

15 . The method of claim 1 , wherein R 2 is naphthalene or benzodioxolane, each of which is optionally substituted with one or more halo, cyano, R 7 , C(O)NR 5 R 7 , —C(O)R 7 , —SO 2 NR 5 R 7 , —SO 2 N(R 5 )(OR 7 ), —(CR 5 R 5 ) q R 7 , —SO 2 R 7 , —(CR 5 R 5 ) q OR 7 or —O(CR 5 R 5 ) q R 7 ; wherein

R 5 is H or C 1 -C 4 alkyl;

R 7 is (i) H or C 1 -C 6 alkyl, cycloalkyl, heterocyclyl, aryl, aralkyl, or heteroaryl, wherein the alkyl, cycloalkyl, heterocyclyl, aryl, aralkyl, and heteroaryl are each optionally substituted with one or more halo or —O(C 1 -C 6 alkyl); and wherein the cycloalkyl, heterocyclyl, aryl, aralkyl, and heteroaryl are each optionally substituted with one or more C 1 -C 6 alkyl; or (ii) alkyl, C 1 -C 4 alkenyl, or C 1 -C 4 alkynyl; or (iii) methyl, trifluoromethyl, ethyl, propyl, isopropyl, t-butyl, 2-propenyl, or 2-propynyl; or (iv) phenyl, benzodioxolane, pyrrolidine, morpholine, piperidine, or pyrrolidinedione; or

when R 5 and R 7 are attached to the same nitrogen atom, R 5 and R 7 may be combined with that nitrogen atom to form a 4 to 7 membered saturated or unsaturated ring system which may contain one or more additional heteroatoms.

16 - 20 . (canceled)

21 . The method of claim 1 , wherein X is N.

22 . The method of claim 1 , wherein R 3 and R 4 are independently hydrogen or C 1 -C 4 alkyl.

23 . The method of claim 1 , wherein R 3 and R 4 combine to form an optionally substituted fused ring system.

24 . The method of claim 23 , wherein R 3 and R 4 combine to form optionally substituted benzene, cyclohexenyl, or cyclopentenyl ring.

25 . (canceled)

26 . The method of claim 24 , or a tautomer, enantiomer or pharmaceutically acceptable salt, hydrate, solvate, complex or prodrug thereof, having formula (Ia):

wherein

R 11 and R 12 are each independently H, C 1 -C 6 alkyl, —O(C 1 -C 6 alkyl), or halo.

27 . The method of claim 26 , wherein (i) R 11 is H and R 12 is H; or (ii) R 11 is H and R 12 is F; or (iii) R 12 is H and R 11 is F, CF 3 , OMe, or methyl.

28 - 29 . (canceled)

30 . The method of claim 1 , wherein the compound is:

N-(benzo[d]thiazol-2-yl)-1-(4-(N-methoxy-N-methylsulfamoyl)benzyl)-1H-indazole-3-carboxamide;

1-(1-(4-((benzo[d][1,3]dioxol-5-yloxy)methyl)benzyl)-5-(trifluoromethyl)-1H-indazol-3-yl)-3-(2,5-dimethoxyphenyl)urea;

1-(4-(methylsulfonyl)benzyl)-N-(thiazol-2-yl)-1H-indazole-3-carboxamide;

N-(benzo[d][1,3]dioxol-5-yl)-1-(4-(methylsulfonyl)benzyl)-1H-indazole-3-carboxamide;

N-(4-methoxyphenyl)-1-(3-phenoxypropyl)-1H-indazole-3-carboxamide;

1-(4-(N-methyl-N-(prop-2-ynyl)sulfamoyl)benzyl)-N-(4-(piperidin-1-yl)phenyl)-1H-indazole-3-carboxamide;

N-(benzo[d]thiazol-2-yl)-1-(4-(N,N-diethylsulfamoyl)benzyl)-1H-indazole-3-carboxamide;

5-methoxy-1-(4-(N-methoxy-N-methylsulfamoyl)benzyl)-N-(4-(piperidin-1-yl)phenyl)-1H-indazole-3-carboxamide;

1-(1-(4-((benzo[d][1,3]dioxol-5-yloxy)methyl)benzyl)-5-(trifluoromethyl)-1H-indazol-3-yl)-3-(3-fluorophenyl)urea;

1-(4-(N,N-diethylsulfamoyl)benzyl)-N-(4-(piperidin-1-yl)phenyl)-1H-indazole-3-carboxamide;

Methyl 4-(3-(1-(4-((3-methoxyphenoxy)methyl)benzyl)-1H-indazol-3-yl)ureido) benzoate;

1-(2,6-dimethoxyphenyl)-3-(1-(4-(trifluoromethyl)benzyl)-1H-indazol-3-yl)urea;

1-(1-((6-chlorobenzo[d][1,3]dioxol-5-yl)methyl)-5-methyl-1H-indazol-3-yl)-3-(2-isopropylphenyl)urea;

1-(3-phenoxypropyl)-N-(4-(piperidin-1-yl)phenyl)-1H-indazole-3-carboxamide;

1-m-tolyl-3-(1-(4-(trifluoromethyl)benzyl)-1H-indazol-3-yl)urea;

1-(3-phenoxypropyl)-N-(thiazol-2-yl)-1H-indazole-3-carboxamide;

N-(benzo[d]thiazol-2-yl)-1-(4-(morpholine-4-carbonyl)benzyl)-1H-indazole-3-carboxamide;

1-(4-(methylsulfonyl)benzyl)-N-(4-(piperidin-1-yl)phenyl)-1H-indazole-3-carboxamide;

N-(4-isopropylphenyl)-1-(4-(morpholine-4-carbonyl)benzyl)-1H-indazole-3-carboxamide;

1-(4-(benzyl(methyl)carbamoyl)benzyl)-N-(4-(trifluoromethyl)phenyl)-1H-indazole-3-carboxamide;

N-(benzo[d][1,3]dioxol-5-yl)-1-(4-(N-methyl-N-(prop-2-ynyl)sulfamoyl)benzyl)-1H-indazole-3-carboxamide;

1-(4-(benzyl(methyl)carbamoyl)benzyl)-N-(4-isopropylphenyl)-1H-indazole-3-carboxamide;

1-(4-(methylsulfonyl)benzyl)-N-(4-(trifluoromethoxy)phenyl)-1H-indazole-3-carboxamide;

N-(benzyloxy)-1-(4-(N-methyl-N-phenylsulfamoyl)benzyl)-1H-indazole-3-carboxamide;

N-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-1-(4-(morpholine-4-carbonyl)benzyl)-1H-indazole-3-carboxamide;

N-(4-isopropylphenyl)-1-(2-phenoxyethyl)-1H-indazole-3-carboxamide;

1-(biphenyl-4-ylmethyl)-N-(4-isopropylphenyl)-1H-indazole-3-carboxamide;

1-(2-fluorobenzyl)-3-(1-(4-((3-methoxyphenoxy)methyl)benzyl)-1H-indazol-3-yl)urea;

1-(1-(4-((benzo[d][1,3]dioxol-5-yloxy)methyl)benzyl)-5-(trifluoromethyl)-1H-indazol-3-yl)-3-(2-(trifluoromethyl)phenyl)urea;

1-(2,3-dihydro-1H-inden-5-yl)-3-(1-(4-((3-methoxyphenoxy)methyl)benzyl)-1H-indazol-3-yl)urea;

1-(1-(4-((benzo[d][1,3]dioxol-5-yloxy)methyl)benzyl)-5-(trifluoromethyl)-1H-indazol-3-yl)-3-(2,4-dimethoxyphenyl)urea;

1-(1-((6-chlorobenzo[d][1,3]dioxol-5-yl)methyl)-1H-indazol-3-yl)-3-(3-methylbenzyl)urea;

N-(1-(4-((2,5-dioxopyrrolidin-1-yl)methyl)benzyl)-1H-indazol-3-yl)quinoxaline-2-carboxamide;

N-(4-methoxyphenyl)-1-(4-(methylsulfonyl)benzyl)-1H-indazole-3-carboxamide;

N-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-1-(4-(methylsulfonyl)benzyl)-1H-indazole-3-carboxamide;

1-(4-(N-methoxy-N-methylsulfamoyl)benzyl)-N-(thiazol-2-yl)-1H-indazole-3-carboxamide;

1-(1-((6-chlorobenzo[d][1,3]dioxol-5-yl)methyl)-1H-indazol-3-yl)-3-(4-methoxyphenethyl)urea;

N-(4-carbamoylphenyl)-1-(4-(morpholine-4-carbonyl)benzyl)-1H-indazole-3-carboxamide;

1-(4-(N,N-diethylsulfamoyl)benzyl)-N-(pyridin-2-yl)-1H-indazole-3-carboxamide;

1-(2-(trifluoromethoxy)phenyl)-3-(1-(4-(trifluoromethyl)benzyl)-1H-indazol-3-yl)urea;

1-(4-(N,N-diethylsulfamoyl)benzyl)-N-(2-methyl-1,3-dioxoisoindolin-5-yl)-1H-indazole-3-carboxamide;

N-(benzo[d][1,3]dioxol-5-yl)-1-(4-tert-butylbenzyl)-1H-indazole-3-carboxamide;

1-(2-(4-fluorophenoxy)ethyl)-N-(4-(piperidin-1-yl)phenyl)-1H-indazole-3-carboxamide;

1-(2-methoxybenzyl)-3-(1-(4-((3-methoxyphenoxy)methyl)benzyl)-1H-indazol-3-yl)urea;

N-(benzo[d][1,3]dioxol-5-yl)-1-(3-phenoxypropyl)-1H-indazole-3-carboxamide;

N-(benzo[d][1,3]dioxol-5-yl)-1-(2-(4-fluorophenoxy)ethyl)-1H-indazole-3-carboxamide;

1-(1-((6-chlorobenzo[d][1,3]dioxol-5-yl)methyl)-1H-indazol-3-yl)-3-(2-fluorobenzyl)urea;

1-(4-tert-butylbenzyl)-N-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-1H-indazole-3-carboxamide;

1-(4-(N-methoxy-N-methylsulfamoyl)benzyl)-N-(pyridin-2-yl)-1H-indazole-3-carboxamide;

N-(benzo[d][1,3]dioxol-5-yl)-1-(biphenyl-4-ylmethyl)-1H-indazole-3-carboxamide;

1-(1-(4-((benzo[d][1,3]dioxol-5-yloxy)methyl)benzyl)-5-(trifluoromethyl)-1H-indazol-3-yl)-3-m-tolylurea;

1-(1-((6-chlorobenzo[d][1,3]dioxol-5-yl)methyl)-1H-indazol-3-yl)-3-(3,5-dimethoxyphenyl)urea;

1-(2,3-dihydro-1H-inden-5-yl)-3-(1-(4-(trifluoromethyl)benzyl)-1H-indazol-3-yl)urea;

1-(3,4-dimethoxyphenyl)-3-(1-(4-(3-methoxyphenoxy)methyl)benzyl)-1H-indazol-3-yl)urea;

1-(1-((6-chlorobenzo[d][1,3]dioxol-5-yl)methyl)-1H-indazol-3-yl)-3-(furan-2-ylmethyl)urea;

N-(4-methoxyphenyl)-1-(2-phenoxyethyl)-1H-indazole-3-carboxamide;

1-(1-(4-((benzo[d][1,3]dioxol-5-yloxy)methyl)benzyl)-5-(trifluoromethyl)-1H-indazol-3-yl)-3-p-tolylurea;

N-(benzo[d][1,3]dioxol-5-yl)-1-(2-phenoxyethyl)-1H-indazole-3-carboxamide;

1-p-tolyl-3-(1-(4-(trifluoromethyl)benzyl)-1H-indazol-3-yl)urea;

1-(2-(4-fluorophenoxy)ethyl)-N-(4-isopropylphenyl)-1H-indazole-3-carboxamide;

1-(4-(morpholine-4-carbonyl)benzyl)-N-(4-(trifluoromethoxy)phenyl)-1H-indazole-3-carboxamide;

N-(4-isopropylphenyl)-1-(4-(methylsulfonyl)benzyl)-1H-indazole-3-carboxamide;

N-(benzo[d][1,3]dioxol-5-yl)-1-(4-(morpholine-4-carbonyl)benzyl)-1H-indazole-3-carboxamide;

N-(4-carbamoylphenyl)-1-(4-(morpholinosulfonyl)benzyl)-1H-indazole-3-carboxamide;

1-(4-tert-butylbenzyl)-N-(4-methoxyphenyl)-1H-indazole-3-carboxamide;

N-(4-isopropylphenyl)-1-(4-(N-methyl-N-(prop-2-ynyl)sulfamoyl)benzyl)-1H-indazole-3-carboxamide;

1-(2-(4-fluorophenoxy)ethyl)-N-(pyridin-2-yl)-1H-indazole-3-carboxamide;

1-(1-(4-(3-methoxyphenoxy)methyl)benzyl)-1H-indazol-3-yl)-3-(2-(trifluoromethoxy)phenyl)urea;

1-(biphenyl-4-ylmethyl)-N-(4-(piperidin-1-yl)phenyl)-1H-indazole-3-carboxamide;

1-(4-tert-butylbenzyl)-N-(4-(trifluoromethoxy)phenyl)-1H-indazole-3-carboxamide;

1-(2-phenoxyethyl)-N-(thiazol-2-yl)-1H-indazole-3-carboxamide;

1-(4-(morpholine-4-carbonyl)benzyl)-N-((tetrahydrofuran-2-yl)methyl)-1H-indazole-3-carboxamide;

1-(3,4-dimethoxyphenethyl)-3-(1-(4-(trifluoromethyl)benzyl)-1H-indazol-3-yl)urea;

1-(biphenyl-4-ylmethyl)-N-(4-methoxyphenyl)-1H-indazole-3-carboxamide;

1-(2-phenoxyethyl)-N-(4-(piperidin-1-yl)phenyl)-1H-indazole-3-carboxamide;

N-(4-carbamoylphenyl)-1-(4-(N-methyl-N-(prop-2-ynyl)sulfamoyl)benzyl)-1H-indazole-3-carboxamide;

1-(4-(methylsulfonyl)benzyl)-N-(pyridin-2-yl)-1H-indazole-3-carboxamide;

1-(1-((6-chlorobenzo[d][1,3]dioxol-5-yl)methyl)-1H-indazol-3-yl)-3-(2-methoxybenzyl)urea;

1-(4-tert-butylbenzyl)-N-(4-(piperidin-1-yl)phenyl)-1H-indazole-3-carboxamide;

1-(4-methoxyphenethyl)-3-(1-(4-((3-methoxyphenoxy)methyl)benzyl)-1H-indazol-3-yl)urea;

N-(4-tert-butylphenyl)-1-(4-(methylsulfonyl)benzyl)-1H-indazole-3-carboxamide;

N-(3,4-dimethoxyphenyl)-1-(4-(methylsulfonyl)benzyl)-1H-indazole-3-carboxamide;

N-phenyl-1-(4-(methylsulfonyl)benzyl)-1H-indazole-3-carboxamide;

N-(4-ethylphenyl)-1-(4-(methylsulfonyl)benzyl)-1H-indazole-3-carboxamide;

N-(2-isopropylphenyl)-1-(4-(methylsulfonyl)benzyl)-1H-indazole-3-carboxamide;

N-(3-methoxyphenyl)-1-(4-(methylsulfonyl)benzyl)-1H-indazole-3-carboxamide;

N-(benzo[d][1,3]dioxol-5-yl)-1-benzyl-1H-indazole-3-carboxamide;

N-(4-hydroxyphenyl)-1-(4-(methylsulfonyl)benzyl)-1H-indazole-3-carboxamide;

N-(4-chlorophenyl)-1-(4-(methylsulfonyl)benzyl)-1H-indazole-3-carboxamide;

N-((1-(4-(methylsulfonyl)benzyl)-1H-indazol-3-yl)methyl)benzo[d][1,3]dioxol-5-amine;

1-(4-isopropylbenzyl)-N-(4-(methylsulfonyl)phenyl)-1H-indazole-3-carboxamide;

N-(benzo[d][1,3]dioxol-5-yl)-1-(4-(morpholine-4-carbonyl)phenethyl)-1H-indazole-3-carboxamide;

N-(benzo[d][1,3]dioxol-5-yl)-1-(4-(piperidine-1-carbonyl)benzyl)-1H-indazole-3-carboxamide;

N-(4-fluorophenyl)-1-(4-(methylsulfonyl)benzyl)-1H-indazole-3-carboxamide;

6-chloro-2-(1-(4-(methylsulfonyl)benzyl)-1H-indazol-3-yl)benzo[d]oxazole;

N-(3-isopropylphenyl)-1-(4-(methylsulfonyl)benzyl)-1H-indazole-3-carboxamide;

N-(benzo[d][1,3]dioxol-5-yl)-1-(pyridin-4-ylmethyl)-1H-indazole-3-carboxamide;

N-(3-isopropyl-1,2,4-thiadiazol-5-yl)-1-(4-(methylsulfonyl)benzyl)-1H-indazole-3-carboxamide;

1-(4-(methylsulfonyl)benzyl)-N-(quinolin-6-yl)-1H-indazole-3-carboxamide;

N-(benzo[d][1,3]dioxol-5-yl)-1-(3-(morpholine-4-carbonyl)benzyl)-1H-indazole-3-carboxamide;

1-(4-(methylsulfonyl)benzyl)-N-(4-(methylsulfonyl)phenyl)-1H-indazole-3-carboxamide;

N-(benzo[d][1,3]dioxol-5-yl)-1-(4-(methylsulfonyl)benzyl)-1H-indazole-3-carbothioamide;

1-(4-(methylsulfonyl)benzyl)-N-(quinolin-3-yl)-1H-indazole-3-carboxamide;

N-(3,4-dimethylphenyl)-1-(4-(methylsulfonyl)benzyl)-1H-indazole-3-carboxamide;

N-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-1-(4-(methylsulfonyl)benzyl)-1H-indazole-3-carboxamide;

N-(benzo[d][1,3]dioxol-5-yl)-1-(pyridin-3-ylmethyl)-1H-indazole-3-carboxamide;

N-(4-acetamidophenyl)-1-(4-(methylsulfonyl)benzyl)-1H-indazole-3-carboxamide;

1-(4-(methylsulfonyl)benzyl)-N-p-tolyl-1H-indazole-3-carboxamide;

N-(4-acetamidophenyl)-1-(4-(trifluoromethyl)benzyl)-1H-indazole-3-carboxamide;

1-(4-(methylsulfonyl)benzyl)-N-(quinoxalin-6-yl)-1H-indazole-3-carboxamide;

N-(3,4-dichlorophenyl)-1-(4-(methylsulfonyl)benzyl)-1H-indazole-3-carboxamide;

1-(4-(methylsulfonyl)benzyl)-N-(4-propylphenyl)-1H-indazole-3-carboxamide;

N-(1,3-dihydrobenzo[c]thiophen-2,2-dioxy-5-yl)-1-(4-(methylsulfonyl)benzyl)-1H-indazole-3-carboxamide;

N-(1-(4-(methylsulfonyl)benzyl)-1H-indazol-3-yl)benzo[d][1,3]dioxole-5-carboxamide;

N-(benzo[d][1,3]dioxol-5-yl)-1-(4-(trifluoromethyl)benzyl)-1H-indazole-3-carboxamide;

1-(4-(methylsulfonyl)benzyl)-N-(naphthalen-2-yl)-1H-indazole-3-carboxamide;

N-(benzo[d][1,3]dioxol-5-yl)-1-(4-(dimethylcarbamoyl)benzyl)-1H-indazole-3-carboxamide;

1-(4-chlorophenyl)-3-(1-(4-(methylsulfonyl)benzyl)-1H-indazol-3-yl)urea;

N-(benzo[d][1,3]dioxol-5-yl)-1-(4-isopropylbenzyl)-1H-indazole-3-carboxamide;

N-(benzofuran-5-yl)-1-(4-(methylsulfonyl)benzyl)-1H-indazole-3-carboxamide;

1-(4-(methylsulfonyl)benzyl)-N-(5,6,7,8-tetrahydronaphthalen-2-yl)-1H-indazole-3-carboxamide;

N-(4-cyclohexylphenyl)-1-(4-(methylsulfonyl)benzyl)-1H-indazole-3-carboxamide;

N-(benzo[d][1,3]dioxol-5-yl)-1-(benzo[d][1,3]dioxol-5-ylmethyl)-1H-indazole-3-carboxamide;

N-(benzo[d][1,3]dioxol-5-yl)-1-(4-tert-butylbenzoyl)-1H-indazole-3-carboxamide;

1-(4-(methylsulfonyl)benzyl)-N-(5-methylthiazol-2-yl)-1H-indazole-3-carboxamide;

1-(4-(methylsulfonyl)benzyl)-N-(4-methylthiazol-2-yl)-1H-indazole-3-carboxamide;

N-(benzo[d][1,3]dioxol-5-yl)-1-(3-(methylsulfonyl)benzyl)-1H-indazole-3-carboxamide;

N-(benzo[d][1,3]dioxol-5-yl)-1-(4-(N,N-dimethylsulfamoyl)benzyl)-1H-indazole-3-carboxamide;

N-(benzo[d][1,3]dioxol-5-yl)-1-(thiophen-3-ylmethyl)-1H-indazole-3-carboxamide;

N-(2,3-dihydro-1H-inden-5-yl)-1-(4-(methylsulfonyl)benzyl)-1H-indazole-3-carboxamide;

N-(benzo[d][1,3]dioxol-5-yl)-1-(4-methylbenzyl)-1H-indazole-3-carboxamide;

N-(benzo[d][1,3]dioxol-5-yl)-1-(4-ethylbenzyl)-1H-indazole-3-carboxamide;

N-(6-methylpyridin-3-yl)-1-(4-(methylsulfonyl)benzyl)-1H-indazole-3-carboxamide;

N-(5-methylpyridin-2-yl)-1-(4-(methylsulfonyl)benzyl)-1H-indazole-3-carboxamide;

N-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-2-(3-(dimethylcarbamoyl)benzyl)-2H-indazole-3-carboxamide;

N-(benzo[d][1,3]dioxol-5-yl)-1-(2-(methylsulfonyl)benzyl)-1H-indazole-3-carboxamide;

N-(benzo[d][1,3]dioxol-5-yl)-1-(4-(morpholinosulfonyl)benzyl)-1H-indazole-3-carboxamide;

1-(4-(dimethylcarbamoyl)benzyl)-N-p-tolyl-1H-indazole-3-carboxamide;

1-(4-(dimethylcarbamoyl)benzyl)-N-(4-isopropylphenyl)-1H-indazole-3-carboxamide;

N-(benzo[d][1,3]dioxol-5-yl)-1-(4-(methylsulfonyl)benzoyl)-1H-indazole-3-carboxamide;

N-(benzo[d][1,3]dioxol-5-yl)-1-(naphthalen-2-ylmethyl)-1H-indazole-3-carboxamide;

N-(benzo[d][1,3]dioxol-5-yl)-1-(4-(pyrrolidine-1-carbonyl)benzyl)-1H-indazole-3-carboxamide;

N-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-1-(4-(morpholine-4-carbonyl)benzyl)-1H-indazole-3-carboxamide;

N-(4-methoxyphenyl)-1-(4-(morpholine-4-carbonyl)benzyl)-1H-indazole-3-carboxamide;

N-(benzo[d][1,3]dioxol-5-yl)-1-(isoxazol-3-ylmethyl)-1H-indazole-3-carboxamide;

N-(benzo[d][1,3]dioxol-5-yl)-1-(4-(methylsulfonyl)benzyl)-1H-indole-3-carboxamide;

N-(2,4-dichlorophenyl)-1-ethyl-1H-pyrazole-3-carboxamide;

N-(benzo[d][1,3]dioxol-5-yl)-1-(4-(methylsulfonyl)benzyl)-1H-pyrazole-3-carboxamide;

N-(benzo[d][1,3]dioxol-5-yl)-1-(4-(methylsulfonyl)benzyl)-4,5,6,7-tetrahydro-1H-indazole-3-carboxamide;

N-(benzo[d][1,3]dioxol-5-yl)-1-(4-(methylsulfonyl)benzyl)-1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-carboxamide;

N-(benzo[d][1,3]dioxol-5-yl)-1-(4-(diethylcarbamoyl)benzyl)-1H-indazole-3-carboxamide;

N-(benzo[d][1,3]dioxol-5-yl)-1-(4-(isopropylsulfonyl)benzyl)-1H-indazole-3-carboxamide;

N-(benzo[d][1,3]dioxol-5-yl)-1-((5-ethylpyridin-2-yl)methyl)-1H-indazole-3-carboxamide;

N-(benzo[d][1,3]dioxol-5-yl)-1-((5-isopropyl-1,2,4-oxadiazol-3-yl)methyl)-1H-indazole-3-carboxamide;

N-(benzo[d][1,3]dioxol-5-yl)-1-((5-ethyl-1,3,4-oxadiazol-2-yl)methyl)-1H-indazole-3-carboxamide;

N-(benzo[d][1,3]dioxol-5-yl)-1-(4-(ethylsulphonyl)benzyl)-1,4-indazole-3-carboxamide;

1-(4-(methylsulphonyl)benzyl)-1H-indazole-3-carboxylic acid;

N-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-1-(4-ethylbenzyl)-1H-indazole-3-carboxamide;

1-(4-ethylbenzyl)-N-(2,2,3,3-tetrafluoro-2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-1H-indazole-3-carboxamide;

N-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-5-fluoro-1-(4-(morpholine-4-carbonyl)benzyl)-1H-indazole-3-carboxamide;

1-(4-(morpholine-4-carbonyl)benzyl)-N-(2,2,3,3-tetrafluoro-2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-1H-indazole-3-carboxamide;

N-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-6-fluoro-1-(4-(morpholine-4-carbonyl)benzyl)-1H-indazole-3-carboxamide; or

N-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-1-(4-(morpholine-4-carbonyl)benzyl)-6-(trifluoromethyl)-1H-indazole-3-carboxamide;

or a tautomer, enantiomer or pharmaceutically acceptable salt, hydrate, solvate, complex or prodrug thereof.

31 . A compound, or a tautomer, enantiomer or pharmaceutically acceptable salt, hydrate, solvate, complex or prodrug thereof, wherein the compound is:

1-(4-(Morpholine-4-carbonyl)benzyl)-N-(4-(trifluoromethoxy)phenyl)-1H-indazole-3-carboxamide;

N-(3,4-Dimethoxyphenyl)-1-(4-(methylsulfonyl)benzyl)-1H-indazole-3-carboxamide;

N-(4-Methoxyphenyl)-1-(4-(morpholine-4-carbonyl)benzyl)-1H-indazole-3-carboxamide;

N-(Benzo[d][1,3]dioxol-5-yl)-1-(4-(methylsulfonyl)benzyl)-1H-indole-3-carboxamide; or

N-(Benzo[d][1,3]dioxol-5-yl)-1-(4-(methylsulfonyl)benzyl)-1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-carboxamide.

32 . A pharmaceutical composition comprising the compound of claim 31 and a pharmaceutically acceptable excipient.

33 . A method for the therapeutic or prophylactic treatment of Duchenne muscular dystrophy, Becker muscular dystrophy, or cachexia, comprising administering the compound of claim 31 .